231 related articles for article (PubMed ID: 27622026)
1. PD-L1 expression as a predictive biomarker for cytokine-induced killer cell immunotherapy in patients with hepatocellular carcinoma.
Chen CL; Pan QZ; Zhao JJ; Wang Y; Li YQ; Wang QJ; Pan K; Weng DS; Jiang SS; Tang Y; Zhang XF; Zhang HX; Zhou ZQ; Zeng YX; Xia JC
Oncoimmunology; 2016 Jul; 5(7):e1176653. PubMed ID: 27622026
[TBL] [Abstract][Full Text] [Related]
2. High number of PD-1 positive intratumoural lymphocytes predicts survival benefit of cytokine-induced killer cells for hepatocellular carcinoma patients.
Chang B; Shen L; Wang K; Jin J; Huang T; Chen Q; Li W; Wu P
Liver Int; 2018 Aug; 38(8):1449-1458. PubMed ID: 29356308
[TBL] [Abstract][Full Text] [Related]
3. PD-L1 expression is a predictive biomarker for CIK cell-based immunotherapy in postoperative patients with breast cancer.
Zhou ZQ; Zhao JJ; Pan QZ; Chen CL; Liu Y; Tang Y; Zhu Q; Weng DS; Xia JC
J Immunother Cancer; 2019 Aug; 7(1):228. PubMed ID: 31455411
[TBL] [Abstract][Full Text] [Related]
4. A prognosis and impact factor analysis of DC-CIK cell therapy for patients with hepatocellular carcinoma undergoing postoperative TACE.
Zhang J; Li H; Gao D; Zhang B; Zheng M; Lun M; Wei M; Duan R; Guo M; Hua J; Liu Q; Bai J; Liu H; Zheng J; Yao H
Cancer Biol Ther; 2018 Jun; 19(6):475-483. PubMed ID: 29400599
[TBL] [Abstract][Full Text] [Related]
5. The efficacy of cytokine-induced killer cell infusion as an adjuvant therapy for postoperative hepatocellular carcinoma patients.
Pan K; Li YQ; Wang W; Xu L; Zhang YJ; Zheng HX; Zhao JJ; Qiu HJ; Weng DS; Li JJ; Wang QJ; Huang LX; He J; Chen SP; Ke ML; Wu PH; Chen MS; Li SP; Xia JC; Zeng YX
Ann Surg Oncol; 2013 Dec; 20(13):4305-11. PubMed ID: 23892527
[TBL] [Abstract][Full Text] [Related]
6. CIK cell cytotoxicity is a predictive biomarker for CIK cell immunotherapy in postoperative patients with hepatocellular carcinoma.
Pan QZ; Liu Q; Zhou YQ; Zhao JJ; Wang QJ; Li YQ; Tang Y; Gu JM; He J; Chen SP; Weng DS; Xia JC
Cancer Immunol Immunother; 2020 May; 69(5):825-834. PubMed ID: 32060687
[TBL] [Abstract][Full Text] [Related]
7. Implication of combined PD-L1/PD-1 blockade with cytokine-induced killer cells as a synergistic immunotherapy for gastrointestinal cancer.
Dai C; Lin F; Geng R; Ge X; Tang W; Chang J; Wu Z; Liu X; Lin Y; Zhang Z; Li J
Oncotarget; 2016 Mar; 7(9):10332-44. PubMed ID: 26871284
[TBL] [Abstract][Full Text] [Related]
8. Blocking the PD-1/PD-L1 axis in dendritic cell-stimulated Cytokine-Induced Killer Cells with pembrolizumab enhances their therapeutic effects against hepatocellular carcinoma.
Zhang W; Song Z; Xiao J; Liu X; Luo Y; Yang Z; Luo R; Li A
J Cancer; 2019; 10(11):2578-2587. PubMed ID: 31258764
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of cytokine-induced killer cell-based immunotherapy for hepatocellular carcinoma.
Jia CC; Chen YH; Cai XR; Li Y; Zheng XF; Yao ZC; Zhao LY; Qiu DB; Xie SJ; Chen WJ; Liu C; Liu QL; Wu XY; Wang TT; Zhang Q
Am J Cancer Res; 2019; 9(6):1254-1265. PubMed ID: 31285957
[TBL] [Abstract][Full Text] [Related]
10. Targeting the crosstalk between cytokine-induced killer cells and myeloid-derived suppressor cells in hepatocellular carcinoma.
Yu SJ; Ma C; Heinrich B; Brown ZJ; Sandhu M; Zhang Q; Fu Q; Agdashian D; Rosato U; Korangy F; Greten TF
J Hepatol; 2019 Mar; 70(3):449-457. PubMed ID: 30414862
[TBL] [Abstract][Full Text] [Related]
11. Cost-Effectiveness of Adjuvant Immunotherapy With Cytokine-Induced Killer Cell for Hepatocellular Carcinoma Based on a Randomized Controlled Trial and Real-World Data.
Cho JY; Kwon SH; Lee EK; Lee JH; Kim HL
Front Oncol; 2021; 11():728740. PubMed ID: 34926248
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant Cytokine-Induced Killer Cell Therapy Improves Disease-Free and Overall Survival in Solitary and Nonmicrovascular Invasive Hepatocellular Carcinoma After Curative Resection.
Chen JL; Lao XM; Lin XJ; Xu L; Cui BK; Wang J; Lin GH; Shuang ZY; Mao YZ; Huang X; Yun JP; Jin JT; Li SP
Medicine (Baltimore); 2016 Feb; 95(5):e2665. PubMed ID: 26844496
[TBL] [Abstract][Full Text] [Related]
13. Serum alpha-fetoprotein measurement in predicting clinical outcome related to autologous cytokine-induced killer cells in patients with hepatocellular carcinoma undergone minimally invasive therapy.
Pan CC; Huang ZL; Li W; Zhao M; Zhou QM; Xia JC; Wu PH
Chin J Cancer; 2010 Jun; 29(6):596-602. PubMed ID: 20507732
[TBL] [Abstract][Full Text] [Related]
14. Sustained efficacy of adjuvant immunotherapy with cytokine-induced killer cells for hepatocellular carcinoma: an extended 5-year follow-up.
Lee JH; Lee JH; Lim YS; Yeon JE; Song TJ; Yu SJ; Gwak GY; Kim KM; Kim YJ; Lee JW; Yoon JH
Cancer Immunol Immunother; 2019 Jan; 68(1):23-32. PubMed ID: 30232520
[TBL] [Abstract][Full Text] [Related]
15. A nomogram for predicting the benefit of adjuvant cytokine-induced killer cell immunotherapy in patients with hepatocellular carcinoma.
Pan QZ; Wang QJ; Dan JQ; Pan K; Li YQ; Zhang YJ; Zhao JJ; Weng DS; Tang Y; Huang LX; He J; Chen SP; Ke ML; Chen MS; Wicha MS; Chang AE; Zeng YX; Li Q; Xia JC
Sci Rep; 2015 Mar; 5():9202. PubMed ID: 25776856
[TBL] [Abstract][Full Text] [Related]
16. Profiling the dynamic expression of checkpoint molecules on cytokine-induced killer cells from non-small-cell lung cancer patients.
Zhang L; Wang J; Wei F; Wang K; Sun Q; Yang F; Jin H; Zheng Y; Zhao H; Wang L; Yu W; Zhang X; An Y; Yang L; Zhang X; Ren X
Oncotarget; 2016 Jul; 7(28):43604-43615. PubMed ID: 27283895
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant cytokine-induced killer cell immunotherapy for hepatocellular carcinoma: a propensity score-matched analysis of real-world data.
Yoon JS; Song BG; Lee JH; Lee HY; Kim SW; Chang Y; Lee YB; Cho EJ; Yu SJ; Sinn DH; Kim YJ; Lee JH; Yoon JH
BMC Cancer; 2019 May; 19(1):523. PubMed ID: 31151419
[TBL] [Abstract][Full Text] [Related]
18. A randomized, controlled trial of postoperative adjuvant cytokine-induced killer cells immunotherapy after radical resection of hepatocellular carcinoma.
Hui D; Qiang L; Jian W; Ti Z; Da-Lu K
Dig Liver Dis; 2009 Jan; 41(1):36-41. PubMed ID: 18818130
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma.
Lee JH; Lee JH; Lim YS; Yeon JE; Song TJ; Yu SJ; Gwak GY; Kim KM; Kim YJ; Lee JW; Yoon JH
Gastroenterology; 2015 Jun; 148(7):1383-91.e6. PubMed ID: 25747273
[TBL] [Abstract][Full Text] [Related]
20. Expression of Programmed Cell Death-Ligands in Hepatocellular Carcinoma: Correlation With Immune Microenvironment and Survival Outcomes.
Liao H; Chen W; Dai Y; Richardson JJ; Guo J; Yuan K; Zeng Y; Xie K
Front Oncol; 2019; 9():883. PubMed ID: 31572677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
